Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Other 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2265Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Leukemia 1500Leukemia, Lymphocytic, Chronic, B-Cell 1120Myelodysplastic Syndromes 963Hematologic Neoplasms 935Lymphoma 739Lymphoma, Non-Hodgkin 654Leukemia, Myelogenous, Chronic, BCR-ABL Positive 532Multiple Myeloma 501Lymphoma, Follicular 467Hodgkin Disease 460Lymphoma, Mantle-Cell 459Burkitt Lymphoma 440Lymphoma, Large B-Cell, Diffuse 433Lymphoma, B-Cell, Marginal Zone 402Recurrence 356Leukemia, Myelomonocytic, Chronic 351Myeloproliferative Disorders 330Leukemia, Myeloid, Chronic-Phase 311Lymphoma, Large-Cell, Immunoblastic 303Congenital Abnormalities 273Neoplasms 271Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 249Blast Crisis 246Leukemia, Myeloid, Accelerated Phase 244Primary Myelofibrosis 221Neoplasms, Plasma Cell 220Waldenstrom Macroglobulinemia 216Lymphoma, T-Cell, Cutaneous 197

Interventions

rasburicase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Hyperuricemia × Other hematologic neoplasm × Clear all
NCT00186940 2017-04-25

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

St. Jude Children's Research Hospital

Completed
16 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome, Hyperuricemia

NCT00628628 2013-08-01

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 2 Completed
82 enrolled 6 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Tumor Lysis Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡